Mersana Therapeutics, Inc. (MRSN)
Automate Your Wheel Strategy on MRSN
With Tiblio's Option Bot, you can configure your own wheel strategy including MRSN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRSN
- Rev/Share 0.2732
- Book/Share -0.248
- PB -1.4754
- Debt/Equity -0.5418
- CurrentRatio 1.8258
- ROIC -1.092
- MktCap 45602483.0
- FreeCF/Share -0.6348
- PFCF -0.5772
- PE -0.6154
- Debt/Assets 0.1487
- DivYield 0
- ROE 9.5801
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MRSN | William Blair | -- | Outperform | -- | -- | Feb. 6, 2025 |
News
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced additional interim Phase 1 clinical data for emiltatug ledadotin (Emi-Le; XMT-1660), the company's B7-H4-directed Dolasynthen ADC. These data are being presented in an oral session today at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, Illinois.
Read More
Mersana Therapeutics, Inc. (MRSN) Q1 2025 Earnings Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q1 2025 Earnings Conference Call May 15, 2025 8:00 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations & Corporate Communications Marty Huber - President & Chief Executive Officer Brian DeSchuytner - Chief Operating Officer & Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Charles Zhu - LifeSci Capital Michael Schmidt - Guggenheim Jonathan Chang - Leerink Partners Colleen Kusy - Baird Andy Hsieh - William Blair Karina Rabayeva - Truist Jeet Mukherjee - BTIG Operator Good morning, and welcome to Mersana Therapeutics First Quarter 2025 Conference Call. Currently …
Read More
CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
Published: May 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ: MRSN), please note that there was a transcription error in the last cell of the first table. The Median OS should have been 5.7 months rather than 1.7 months. The corrected release follows:
Read More
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.16 per share a year ago.
Read More
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Negative
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.16 per share a year ago.
Read More
Mersana Therapeutics to Present at Upcoming Investor Conferences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in the following upcoming investor events:
Read More
Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2024 on Monday, March 3, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
Read More
About Mersana Therapeutics, Inc. (MRSN)
- IPO Date 2017-06-28
- Website https://www.mersana.com
- Industry Biotechnology
- CEO Dr. Martin H. Huber M.D.
- Employees 102